Patent · US Active

Methods of producing RPE cells

US10889801B2 · kind B2 · utility

2Cited by

0References

17Claims

0Family size

Assignee

BioLamina AB · SE

Inventors

Outi Hovatta · Solna, SE
Karl Tryggvason · Stockholm, SE

Key dates

Filing date	Dec 3, 2013
Grant date	Jan 12, 2021
Priority date	—
Expiry date	Dec 3, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2533/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.